Genmab — Juli 2020
-
"World bispecific" har conference sidst i september og så vidt jeg kan se er Genmabs fravær påfaldende. Ydermere er der dagen op til en dag med særlig fokus på CD3 bispecifics https://bispecific.com/whats-on/agenda-at-a-glance/
-
On the Amivantamab trial note that the purpose is two-fold: In one part Lazertinib (arm C) is compared to Osimertinib (arm B), this part is blinded. In the other part Amivantamab is tested as add-on to Lazertinib (arm A) this part is open label, so JnJ can follow during the trial if this combo outperforms the blinded part, which is what we hope for
-
-
Her fungerer det.
-
Må indrømme jeg har solgt lidt i dag... jeg kan ikke lide den corona,,, og dens konsekvenser.... som ingen kender omfanget af ....
-
GBR1342 cd3xcd38 is still alive https://www.clinicaltrials.gov/ct2/show/NCT03309111?term=gbr1342&draw=2&rank=1
-
USD sales will give a lower revenue in DKK. There is a partial natural hedge due to costs made in the US, eg with the US office or trial costs. On the other hand it will raise USD sales number for Daratumumab sales in Europe, thereby increasing the Dara royalty revenue amount (in USD
)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind